Introduction Activating mutations in the epidermal growth factor receptor gene (EGFR)
predict for prolonged progression-free survival in patients with advanced non–small cell …

Gefitinib is effective as first‐line therapy for advanced nonsmall cell lung cancer (NSCLC).
However, after failure of gefitinib, it is unknown whether any second‐line regimens could …

Purpose Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington,
DE), an orally active epidermal growth factor receptor tyrosine kinase inhibitor, may enhance …

Lung cancer is the leading cause of cancer-related death in the world. Prior to the era of
targeted therapy, platinum-based doublet chemotherapy was the first-line therapy of choice …

9005 Background: Although EGFR-TKI alone has been a standard first-line treatment for pts
with advanced NSCLC with EGFR mutations, our phase II study (NEJ005) showed …

7503 Background: EGFR tyrosine kinase activating mutations are present in 10-26% of
NSCLC tumors and are associated with increased response to gefitinib and erlotinib …

Aim: Most patients (pts) with EGFR mutation-positive NSCLC respond to 1st-line EGFR
tyrosine kinase inhibitors, but later acquire resistance. The Phase III, double-blind IRESSA …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) were initially
established as second-or third-line treatment of advanced non-small-cell lung cancer …

Background The phase III, randomized, open-label ENSURE study (NCT01342965)
evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China …

Gefitinib, erlotinib and afatinib are approved for first‐line treatment of advanced non‐small
cell lung cancer (NSCLC) bearing an activating epidermal growth factor receptor (EGFR) …